Complications, morbidity and mortality of nonalcoholic fatty liver disease A Mantovani, E Scorletti, A Mosca, A Alisi, CD Byrne, G Targher Metabolism 111, 154170, 2020 | 426 | 2020 |
Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease E Scorletti, CD Byrne Annual review of nutrition 33 (1), 231-248, 2013 | 366 | 2013 |
Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study E Scorletti, L Bhatia, KG McCormick, GF Clough, K Nash, L Hodson, ... Hepatology 60 (4), 1211-1221, 2014 | 355 | 2014 |
A new perspective on NAFLD: Focusing on lipid droplets E Scorletti, RM Carr Journal of hepatology 76 (4), 934-945, 2022 | 186 | 2022 |
Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents A Mosca, V Nobili, R De Vito, A Crudele, E Scorletti, A Villani, A Alisi, ... Journal of hepatology 66 (5), 1031-1036, 2017 | 181 | 2017 |
Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease E Scorletti, PR Afolabi, EA Miles, DE Smith, A Almehmadi, A Alshathry, ... Gastroenterology 158 (6), 1597-1610. e7, 2020 | 164 | 2020 |
Nonalcoholic fatty liver disease in children JP Mann, L Valenti, E Scorletti, CD Byrne, V Nobili Seminars in liver disease 38 (01), 001-013, 2018 | 164 | 2018 |
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action E Scorletti, CD Byrne Molecular aspects of medicine 64, 135-146, 2018 | 159 | 2018 |
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized … A Mantovani, CD Byrne, E Scorletti, CS Mantzoros, G Targher Diabetes & metabolism 46 (6), 427-441, 2020 | 126 | 2020 |
Diagnosis and management of non-alcoholic fatty liver disease E Jennison, J Patel, E Scorletti, CD Byrne Postgraduate medical journal 95 (1124), 314-322, 2019 | 121 | 2019 |
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial E Scorletti, AL West, L Bhatia, SP Hoile, KG McCormick, GC Burdge, ... Journal of hepatology 63 (6), 1476-1483, 2015 | 121 | 2015 |
Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults CD Byrne, J Patel, E Scorletti, G Targher Bmj 362, 2018 | 102 | 2018 |
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments E Scorletti, PC Calder, CD Byrne Endocrine 40, 332-343, 2011 | 92 | 2011 |
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study L Hodson, L Bhatia, E Scorletti, DE Smith, NC Jackson, ... European journal of clinical nutrition 71 (8), 973-979, 2017 | 77 | 2017 |
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression L Bhatia, E Scorletti, N Curzen, GF Clough, PC Calder, CD Byrne Atherosclerosis 246, 13-20, 2016 | 71 | 2016 |
Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD V Nobili, A Alisi, G Musso, E Scorletti, PC Calder, CD Byrne Critical reviews in clinical laboratory sciences 53 (2), 106-120, 2016 | 59 | 2016 |
Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis P Wainwright, E Scorletti, CD Byrne Current diabetes reports 17, 1-8, 2017 | 53 | 2017 |
Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty … E Scorletti, L Bhatia, KG McCormick, GF Clough, K Nash, PC Calder, ... Contemporary clinical trials 37 (2), 301-311, 2014 | 50 | 2014 |
Low levels of low-density lipoprotein cholesterol and mortality outcomes in non-statin users KC Sung, JH Huh, S Ryu, JY Lee, E Scorletti, CD Byrne, JY Kim, DS Hyun, ... Journal of Clinical Medicine 8 (10), 1571, 2019 | 46 | 2019 |
Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD V Nobili, A Alisi, A Mosca, C Della Corte, S Veraldi, R De Vito, ... Liver International 38 (2), 342-349, 2018 | 45 | 2018 |